SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

Summary
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.
Competing Interest Statement
K.S.C., N.W., J.S.M., and B.S.G. are inventors on International Patent Application No. WO/2018/081318 entitled Prefusion Coronavirus Spike Proteins and Their Use. K.S.C., O.M.A., G.B.H., N.W., D.W., J.S.M, and B.S.G. are inventors on US Patent Application No. 62/972,886 entitled 2019-nCoV Vaccine. R.S.B. filed an invention report for the SARS-CoV-2 MA virus (UNC ref. #18752).
Subject Area
- Biochemistry (7568)
- Bioengineering (5523)
- Bioinformatics (20789)
- Biophysics (10327)
- Cancer Biology (7980)
- Cell Biology (11638)
- Clinical Trials (138)
- Developmental Biology (6602)
- Ecology (10202)
- Epidemiology (2065)
- Evolutionary Biology (13615)
- Genetics (9541)
- Genomics (12846)
- Immunology (7920)
- Microbiology (19541)
- Molecular Biology (7657)
- Neuroscience (42093)
- Paleontology (308)
- Pathology (1258)
- Pharmacology and Toxicology (2202)
- Physiology (3267)
- Plant Biology (7040)
- Synthetic Biology (1951)
- Systems Biology (5426)
- Zoology (1117)